Meta-Analysis of IBS-C Drug Trials: Efficacy and Safety of Linaclotide and Plecanatide

A 2025 systematic review and meta-analysis of 9 randomized controlled trials involving 5,718 patients with irritable bowel syndrome with constipation (IBS-C). The dataset, authored by Zihao Zhou and last updated in April 2026, compares the efficacy and safety of Guanylyl cyclase C agonists (linaclotide and plecanatide) against placebo, using FDA composite endpoints and safety outcomes.

Use Cases

• Compare relative risk (RR) for FDA composite endpoint achievement across different drug dosages.
• Analyze the trade-off between symptom improvement and adverse events like diarrhea based on reported incidence rates.
• Validate meta-analytic statistical methods using results from RevMan and Stata software outputs.
• Assess methodological quality of included trials based on the Cochrane Risk of Bias Assessment Tool.

Strengths

• Includes data from 9 randomized controlled trials with a total of 5,718 patient records.
• Reports specific relative risk (RR) values and 95% confidence intervals for primary and safety outcomes.
• Follows a registered systematic review protocol (PROSPERO CRD420251168079).

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is 190.5 KB, indicating a limited scope focused on summary statistics rather than individual patient data.

Provenance

Source

Systematic review of PubMed, Embase, Cochrane Library, Web of Science, and ClinicalTrials.gov.

Collection Method

Meta-analysis of identified randomized controlled trials using RevMan 5.4 and Stata 18.0 software.

Time Range

From database inception to 7 September 2025.

Freshness

Last updated 2026-04-10 05:58:43.

Geography

null